01—Abstract
Summary
Summary of the 10-K filed February 26, 2021. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc.'s 2020 Form 10-K highlights a pivotal year driven by the rapid development and emergency use authorization (EUA) of its COVID-19 vaccine (mRNA-1273).
The company's novel mRNA platform demonstrated its potential, leading to significant revenue growth primarily from product sales and government grants, a stark contrast to previous years dominated by collaboration revenue. Despite substantial operating losses, reflecting heavy investment in R&D and manufacturing scale-up, Moderna ended 2020 with a strong cash position, bolstered by vaccine supply agreements and equity offerings. The report underscores the company's strategic focus on maximizing the impact of its COVID-19 vaccine, advancing its pipeline, generating proof-of-concept data in new therapeutic areas, and expanding the application of mRNA technology.
Key risks identified include manufacturing complexities, potential vaccine ineffectiveness against emerging variants, patent challenges, and the inherent uncertainties of developing novel mRNA-based medicines. The company's future success hinges on its ability to navigate these risks, secure further funding, and successfully bring its diverse pipeline of vaccines and therapeutics to market.
02—Key points
Key Highlights
- Moderna received Emergency Use Authorization (EUA) for its COVID-19 vaccine (mRNA-1273) from the FDA and other global regulatory bodies in late 2020.
- Total revenue surged to $803.4 million in 2020, a significant increase from $60.2 million in 2019, primarily driven by $199.9 million in COVID-19 vaccine product sales and a substantial increase in grant revenue from BARDA ($516.7 million) for vaccine development.
- The company reported a net loss of $747.1 million for 2020, reflecting continued heavy investment in research and development ($1.37 billion) and manufacturing scale-up.
- As of December 31, 2020, Moderna had $5.25 billion in cash, cash equivalents, and investments, supported by $11.7 billion in committed orders for its COVID-19 vaccine and $1.85 billion raised from equity offerings in 2020.
- Moderna's pipeline includes 24 development programs across six modalities: prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
- The company faces significant risks related to manufacturing scale-up, potential vaccine ineffectiveness against SARS-CoV-2 variants, and the evolving regulatory landscape for mRNA-based medicines.
- Moderna is actively expanding its manufacturing capabilities, both internally and through strategic partnerships with CMOs like Lonza and Catalent, to meet global demand for its COVID-19 vaccine.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2020, Moderna, Inc. lost $0.93.
- Revenue$803.0M100.0%
- Cost of revenue−$8.0M1.0%
- Gross profit$795.0M99.0%
- Operating costs−$1.56B194.0%
- Operating income−$763.0M95.0%
- Interest, other & tax$16.0M2.0%
- Net income−$747.0M93.0%
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 26, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $803.00M$60.00M | +1238.3% |
| Cost of Revenue | $8.00M$0 | — |
| Gross Profit | $795.00M$60.00M | +1225.0% |
| R&D Expenses | $1.37B$496.00M | +176.2% |
| Operating Expenses | $1.57B$605.93M | +158.4% |
| Operating Income | -$763.00M-$546.00M | −39.7% |
| Net Income | -$747.00M-$514.00M | −45.3% |
| EPS (Basic) | $-1.96$-1.55 | −26.5% |
| EPS (Diluted) | $-1.96$-1.55 | −26.5% |
| Shares Outstanding (Basic) | 381.00M330.80M | +15.2% |
| Shares Outstanding (Diluted) | 381.00M331.00M | +15.1% |
05—Questions
Frequently Asked Questions
What is Moderna's primary focus as highlighted in this 10-K filing?
Moderna's primary focus, as highlighted in this filing, is on the development, manufacturing, and commercialization of mRNA-based medicines and vaccines. The company's pivotal achievement in 2020 was the rapid development and Emergency Use Authorization (EUA) of its COVID-19 vaccine (mRNA-1273), which significantly impacted its financial results and operational priorities.
What are the key financial takeaways from Moderna's 2020 performance?
Financially, 2020 was a transformative year for Moderna. Total revenue saw a dramatic increase to $803.4 million, driven by significant product sales from the COVID-19 vaccine and substantial grant revenue from BARDA. Despite this revenue growth, the company continued to incur substantial operating expenses, particularly in research and development ($1.37 billion), leading to a net loss of $747.1 million. However, strong demand for the COVID-19 vaccine resulted in significant upfront payments and committed orders, contributing to a robust cash position of $5.25 billion by year-end, which is crucial for funding ongoing R&D and manufacturing scale-up.
What are the major risks and challenges facing Moderna, according to this filing?
Moderna identifies several key risks and challenges. These include the complexities and scale-up challenges associated with manufacturing mRNA products, the potential for the COVID-19 vaccine to be less effective against emerging SARS-CoV-2 variants, competition from other vaccine developers, patent challenges, and the inherent regulatory and clinical development risks associated with a novel class of medicines like mRNA therapeutics. The company also highlights its reliance on third-party manufacturers and suppliers, and the potential for disruptions due to the ongoing COVID-19 pandemic.
How is Moderna leveraging its mRNA platform beyond the COVID-19 vaccine?
Beyond its COVID-19 vaccine, Moderna is actively developing a diverse pipeline of 24 mRNA development programs across six modalities: prophylactic vaccines (including candidates for flu, HIV, and Nipah virus), systemic secreted and cell surface therapeutics, cancer vaccines (personalized and shared neoantigen), intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics. The company emphasizes its 'platform' approach, where learnings and technologies from one program or modality can accelerate development across others.
06—Continue